Bayer, one of the largest names in agriculture and pharmaceuticals, has recently announced that it is transferring its glyphosate business to an independent company called Ruveon. This decision comes after legal successes and major financial agreements, aiming to improve performance in the challenging U.S. market.
Why Ruveon?
The new company, Ruveon, based in St. Louis, Missouri, will focus on all aspects of the glyphosate business in the United States, from pricing to production and logistics. Bayer has stated that this change will allow Ruveon to respond more independently and quickly to the specific needs of the market, especially against similar products available in this market.
This decision comes at a time when Bayer is facing a heavy wave of lawsuits worth billions of dollars due to the potential carcinogenic risks of glyphosate, particularly the well-known product Roundup. In February, the company signed a $7.25 billion agreement to settle these lawsuits, which has also received preliminary approval.
Victory in Court
Bayer has recently achieved a significant victory in the U.S. Supreme Court. According to this ruling, Bayer cannot be legally pursued for failing to include cancer warnings on its product packaging. This ruling helps Bayer reduce the legal foundations of thousands of lawsuits related to Roundup and positions itself better.
While Bayer continues to deny the potential risks of glyphosate, these developments indicate that the pharmaceutical giant is striving to adapt to a complex market and legal environment. Could this structural change help Bayer navigate its legal storms and achieve a sustainable future?
